Janus Henderson Group PLC Has $64.01 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Janus Henderson Group PLC increased its position in Perspective Therapeutics, Inc. (NYSE:CATX) by 8.0% during the third quarter, HoldingsChannel reports. The institutional investor owned 4,799,352 shares of the company’s stock after acquiring an additional 355,685 shares during the period. Janus Henderson Group PLC owned about 0.07% of Perspective Therapeutics worth $64,014,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in CATX. nVerses Capital LLC acquired a new position in Perspective Therapeutics during the third quarter valued at approximately $57,000. US Bancorp DE grew its holdings in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares during the last quarter. Victory Capital Management Inc. acquired a new position in Perspective Therapeutics during the second quarter valued at approximately $117,000. Point72 DIFC Ltd acquired a new position in Perspective Therapeutics during the second quarter valued at approximately $118,000. Finally, Intech Investment Management LLC acquired a new position in Perspective Therapeutics during the third quarter valued at approximately $137,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. UBS Group assumed coverage on Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target on the stock. Wedbush reiterated an “outperform” rating and set a $11.00 price target (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Truist Financial started coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They set a “buy” rating and a $21.00 price target on the stock. Oppenheimer reduced their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.14.

Insider Buying and Selling

In related news, CFO Jonathan Robert Hunt acquired 12,829 shares of the business’s stock in a transaction on Monday, November 25th. The stock was bought at an average cost of $3.82 per share, with a total value of $49,006.78. Following the completion of the acquisition, the chief financial officer now owns 48,800 shares in the company, valued at $186,416. The trade was a 35.66 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Johan M. Spoor acquired 8,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were bought at an average cost of $3.77 per share, with a total value of $30,160.00. Following the completion of the acquisition, the chief executive officer now owns 36,257 shares of the company’s stock, valued at approximately $136,688.89. This trade represents a 28.31 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 41,595 shares of company stock valued at $156,785 over the last ninety days. 3.52% of the stock is owned by company insiders.

Perspective Therapeutics Price Performance

CATX opened at $3.72 on Friday. Perspective Therapeutics, Inc. has a 1-year low of $2.28 and a 1-year high of $19.05. The business has a 50 day moving average of $9.93 and a 200-day moving average of $12.00.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). The firm had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Equities research analysts predict that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.